Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus

Exclusion Criteria

• •History of clinical manifestations of significant metabolic, hepatic, renal, and hematological pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders other than type 2 diabetes mellitus
• •Uncontrolled diabetes
• •Exclusionary labs - fasting blood sugar, low hemoglobin, elevated liver function tests, positive result for human immunodeficiency virus, hepatitis B surface antigen, and anti-hepatitis C virus
• •Low creatinine clearance
• •History of myocardial infarction within past 90 days or other cardiovascular conditions
• •Prior exposure to S-707106
• •Treatment with investigational study drug within 30 days of study admission day